News Sentiment

RXST sentiment intelligence

Rxsight Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 5.55 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+12.1% over one week, +17.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction 12.1% Price confirming higher
Trend fit Trend inactive 17.3% over four weeks
Fair value -80.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 37
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 18
Stock Titan 8
GlobeNewswire 6
Investing.com 4
Moomoo 2
Simply Wall Street 2
VisionMonday.com 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 19
Deals and strategy 6
Analyst action 4
Regulatory and legal 4
Guidance 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Stock Titan Direct company coverage

BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight

BlackRock Portfolio Management LLC has disclosed a 7.2% beneficial ownership stake in RxSight, Inc. (RXST), holding 2,982,816 shares as of June 30, 2026. The firm maintains sole voting power over 2,618,543 shares and sole dispositive power over all 2,982,816 shares, with no share

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jul 2026 15:10
Source
Stock Titan
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)

Healthcare companies RxSight (RXST), Kazia Therapeutics (KZIA), and Crescent Biopharma (CBIO) have recently received analyst coverage. BTIG analysts offered ratings for RxSight and Kazia Therapeutics, while H.C. Wainwright provided an update for Crescent Biopharma. The article de

Tone
Neutral 50/100
Event
Analyst action
Published
17 Jul 2026 11:42
Source
The Globe and Mail
Market source Direct company coverage

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight (RXST) shares increased by 6.1% to $5.57, driven by high trading volume and investor optimism regarding an upcoming leadership transition. Aziz Mottiwala is set to become the new President and CEO on July 20, 2026. Despite a projected quarterly loss of $0.21 per share and

Tone
Positive 65/100
Event
Market update
Published
17 Jul 2026 08:11
Source
Market source
Simply Wall Street Direct company coverage

Alcon (SWX:ALC) After The RxSight Deal Is The Growth Story Already Priced In

Alcon (SWX:ALC) has gained attention after a collaboration with RxSight for adjustable presbyopia-correcting intraocular lenses, leading to recent share price momentum. However, despite a "25.7% Undervalued" narrative targeting a fair value of CHF76.62 due to new product launches

Tone
Positive 66/100
Event
Deals and strategy
Published
16 Jul 2026 19:41
Source
Simply Wall Street
Investing.com Direct company coverage

RxSight names Aziz Mottiwala as new CEO effective July 20

RxSight, Inc. has announced the appointment of Aziz Mottiwala as its new President and Chief Executive Officer, effective July 20. Mottiwala succeeds Ron Kurtz, M.D., who will transition to Chief Medical Officer. This leadership change comes as RxSight's stock has faced significa

Tone
Negative 34/100
Event
Market update
Published
16 Jul 2026 11:42
Source
Investing.com
VisionMonday.com Direct company coverage

RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO

RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as president and CEO, effective July 20, 2026. Current CEO Ron Kurtz, MD, will transition to chief medical officer and resign from the board of directors, with Mottiwala joining the board. This change

Tone
Positive 70/100
Event
Market update
Published
16 Jul 2026 04:40
Source
VisionMonday.com
Orange County Business Journal Direct company coverage

RxSight Appoints Aziz Mottiwala as CEO

RxSight Inc. has appointed Aziz Mottiwala, former Tarsus Pharmaceuticals Chief Commercial Officer, as its new chief executive. Mottiwala replaces Ron Kurtz, who served as CEO for a decade and will now transition to chief medical officer. Following the announcement, shares in RxSi

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 21:44
Source
Orange County Business Journal
Stock Titan Direct company coverage

RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition, appointing Aziz Mottiwala as President and CEO, effective July 20, 2026. Former CEO Ron Kurtz, M.D., will transition to Chief Medical Officer. Mottiwala's compensation package includes a $750,000 base salary, guarant

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 20:44
Source
Stock Titan
Investing.com Canada Direct company coverage

RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com

RxSight, Inc. has announced Aziz Mottiwala as its new President and CEO, effective July 20, replacing Ron Kurtz, who will become Chief Medical Officer. This leadership change occurs as RxSight's stock has seen a significant decline, though InvestingPro analysis suggests it may be

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:44
Source
Investing.com Canada
Stock Titan Direct company coverage

RxSight CEO Ron Kurtz to Continue as Chief Medical Officer

RxSight (NASDAQ: RXST) announced a leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer. Ron Kurtz, M.D., the current CEO, will transition to Chief Medical Officer, focusing on technology and clinical development, and w

Tone
Positive 73/100
Event
Market update
Published
15 Jul 2026 20:44
Source
Stock Titan
GlobeNewswire Direct company coverage

RxSight Announces Appointments of Aziz Mottiwala as Chief

RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as President and Chief Executive Officer, effective July 20, 2026. He succeeds Ron Kurtz, M.D., who will continue as the Chief Medical Officer. The company highlighted Mottiwala's extensive commercial

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 20:44
Source
GlobeNewswire
Moomoo Direct company coverage

Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight has announced significant leadership changes, appointing Aziz Mottiwala as the new Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer, effective immediately. Mr. Mottiwala previously served as Chief Commercial Officer, while Dr. Kurtz was a co-founder an

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 20:40
Source
Moomoo
Market source Direct company coverage

Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology

Alcon and RxSight have partnered to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, combining Alcon's optical designs with RxSight's light-adjustable technology. This collaboration aims to allow surgeons to fine-tune visual outcomes pos

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 22:44
Source
Market source
Ophthalmology Times Europe Direct company coverage

Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs

Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs, allowing surgeons to f

Tone
Positive 94/100
Event
Deals and strategy
Published
11 Jul 2026 14:11
Source
Ophthalmology Times Europe
Market source Direct company coverage

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight reported a 20% year-over-year decline in Q2 sales, excluding collaboration revenue, reaching approximately $27 million, with Light Adjustable Lens unit sales down 10%. Despite these near-term headwinds attributed to competitive launches and weaker consumer sentiment, the

Tone
Negative 34/100
Event
Earnings
Published
11 Jul 2026 01:41
Source
Market source
GuruFocus Direct company coverage

RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties

RxSight Inc (RXST), a medical device company, is under investigation by Glancy Prongay Wolke & Rotter LLP for potential breaches of fiduciary duties by its board of directors. This follows a significant decline in its Q2 2025 financial performance, attributed to challenges in sal

Tone
Negative 29/100
Event
Regulatory and legal
Published
10 Jul 2026 20:41
Source
GuruFocus
The AI Journal Direct company coverage

Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

Glancy Prongay Wolke & Rotter LLP has announced an investigation into RxSight, Inc. (RXST) concerning potential breaches of fiduciary duties by its board of directors. This comes after RxSight reported significant declines in its preliminary Q2 2025 financial results, including L

Tone
Negative 30/100
Event
Regulatory and legal
Published
10 Jul 2026 17:41
Source
The AI Journal
Simply Wall Street Direct company coverage

Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E?

Alcon (SWX:ALC) recently announced a collaboration with RxSight to co-develop intraocular lenses, putting its cataract technology in focus, yet its stock is down 11% over 90 days and 21% annually. While a "most popular narrative" suggests the stock is 29.5% undervalued with a fai

Tone
Positive 60/100
Event
Market update
Published
09 Jul 2026 01:41
Source
Simply Wall Street
FinancialContent Direct company coverage

Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

The Law Offices of Howard G. Smith announced an investigation into potential breaches of fiduciary duties by the board of directors of RxSight, Inc. (RXST). This follows RxSight's preliminary Q2 2025 financial results, which showed significant declines in sales and revenue, leadi

Tone
Negative 25/100
Event
Regulatory and legal
Published
08 Jul 2026 16:00
Source
FinancialContent
TradingView Direct company coverage

Price to book forward of RxSight, Inc. – NASDAQ:RXST

This article provides the "Price to book forward" financial metric for RxSight, Inc. (NASDAQ: RXST). It displays the period, value, change, and percentage change for this specific financial indicator. The content is presented within the context of TradingView's platform, indicati

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 05:11
Source
TradingView
VisionMonday.com Direct company coverage

RxSight, Inc. Reports Preliminary Financial Results for the Second Quarter of 2026

RxSight, Inc. has released preliminary financial results for Q2 2026, projecting total revenue between $32 million and $34 million, including revenue from a strategic collaboration with Alcon. Despite commercial headwinds, the company is accelerating investments in its sales forc

Tone
Positive 63/100
Event
Earnings
Published
08 Jul 2026 04:39
Source
VisionMonday.com
Investing.com Direct company coverage

Alcon, RxSight partner on adjustable lens technology

Alcon and RxSight Inc. have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses for cataract surgery patients. RxSight will receive an upfront payment of $60 million and potentially an additional $140 million based on development

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 20:46
Source
Investing.com
Business Wire Direct company coverage

The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

The Law Offices of Frank R. Cruz has initiated an investigation into potential breaches of fiduciary duty by the board of directors of RxSight, Inc. (RXST) following significant declines in the company's Q2 2025 financial results and a lowered full-year guidance. This investigati

Tone
Negative 19/100
Event
Regulatory and legal
Published
07 Jul 2026 19:11
Source
Business Wire
Investing.com Direct company coverage

BofA cuts RxSight stock price target on weak Q2 sales, guidance

BofA Securities has lowered its price target for RxSight Inc. (RXST) to $6.50 from $8.00, maintaining an Underperform rating, due to weak preliminary second-quarter sales and a reduced 2026 guidance. The company reported preliminary Q2 sales of $27 million, below estimates, and l

Tone
Negative 29/100
Event
Analyst action
Published
07 Jul 2026 17:11
Source
Investing.com